Evaluation of the Use of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Statin Intolerant Patients of an Outpatient Lipid Clinic

2017 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []